查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595275

周边动脉疾病治疗药物市场：按治疗类型、适应症阶段和最终用户划分 - 全球预测 2025-2030

Peripheral Arterial Disease Therapeutics Market by Treatment Type (Medications, Surgical Treatments), Indication Stage (Asymptomatic, Ischemic Rest Pain, Mild Claudication), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

周边动脉疾病药物市场2023年估值为47.5亿美元，预计2024年将达到51.4亿美元，复合年增长率为8.73%，到2030年将达到85.5亿美元。

周边动脉疾病(PAD) 治疗市场的范围和定义包括 PAD 的诊断、治疗和管理。 PAD 是一种因动脉狭窄而导致四肢血流减少的疾病。对有效 PAD 治疗的需求源自于糖尿病、高血压和肥胖等危险因子的日益普及。应用领域包括药品（抗血小板药物、他汀类药物等）、医疗设备（支架、血管成形术球囊）和旨在改善患者治疗效果的生活型态管理计画。最终使用领域主要包括医院、专科诊所和居家医疗环境。根据市场洞察，推动成长的关键因素包括微创治疗的进步、人们对週边动脉疾病（PAD）认识的提高以及易患血管疾病的老年人口迅速增加。最近的机会包括药物释放型技术、生技药品和提供医疗干预和数位患者监测的全面医疗保健解决方案的开发。为了利用这些机会，公司应专注于个人化医疗的研发投资，并与高科技公司合作开发数位健康解决方案。儘管成长前景广阔，但该市场仍面临一些限制，例如先进治疗的高成本、监管障碍以及患者对治疗方法依从性的挑战。此外，新兴地区获得医疗保健的机会有限以及缺乏全面的诊断设施也限制了市场的成长。创新研究领域包括探索基因疗法、动脉修復的再生医学，以及开发用于早期检测和管理 PAD 的人工智慧技术。市场的性质是动态的，并受到技术进步和医疗保健政策变化的高度影响。为了确保可持续的业务成长，公司正在优先考虑将治疗创新与以患者为中心的护理模式相结合的适应性策略，并应考虑扩大服务欠缺地区的潜在合作关係。

主要市场统计
基准年[2023] 47.5亿美元
预测年份 [2024] 51.4亿美元
预测年份 [2030] 85.5亿美元
复合年增长率（%） 8.73%

市场动态：快速发展的周边动脉疾病治疗市场的关键市场洞察

周边动脉疾病药物市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 随着老年人口的增加，周边动脉疾病的盛行率也随之增加
    • 世界日益转向不健康的生活方式
    • 对微创血管内治疗的偏好日益增加
  • 市场限制因素
    • 治疗周边动脉疾病相关的高成本
  • 市场机会
    • 周边动脉疾病先进治疗方法的研究与开发
    • 周边动脉疾病治疗产品核可数量增加
  • 市场挑战
    • 缺乏熟练周边动脉疾病设备的专家和医生

波特五力：驾驭周边动脉疾病药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解周边动脉疾病药物市场的外部影响

外部宏观环境因素在塑造周边动脉疾病治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解周边动脉疾病治疗药物市场的竞争状况

周边动脉疾病治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

周边动脉疾病药物市场供应商的 FPNV 定位矩阵绩效评估

FPNV 定位矩阵是评估周边动脉疾病药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划周边动脉疾病治疗药物市场的成功之路

周边动脉疾病治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着人口老化的加剧，周边动脉疾病的发生率也增加
      • 世界各地向不健康生活方式的转变有所增加
      • 人们对微创血管内手术的兴趣日益浓厚
    • 抑制因素
      • 治疗周边动脉疾病相关的高费用
    • 机会
      • 周边动脉疾病先进治疗方法的研究与开发
      • 治疗周边动脉疾病的药物核准增加
    • 任务
      • 缺乏熟悉周边动脉疾病设备的熟练专家和医生
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的周边动脉疾病治疗药物市场

  • 药品
    • 抗高血压药
    • 草酸萘呋酯
    • 他汀类药物
  • 手术治疗
    • 血管成形术
    • 动脉绕道术

第七章依适应症阶段周边动脉疾病治疗药物市场

  • 无症状
  • 缺血性休息痛
  • 轻度跛行
  • 中度/重度跛行
  • 溃疡/坏疽

第八章周边动脉疾病治疗药物市场：依最终用户分类

  • 医院
  • 专科诊所

第九章北美及南美周边动脉疾病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区周边动脉疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲周边动脉疾病治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Alucent Biomedical Inc.
  • AnGes, Inc.
  • AngioDynamics, Inc.
  • ARCA biopharma, Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cook Group Incorporated
  • Helixmith Co., Ltd.
  • Koninklijke Philips NV
  • LeMaitre Vascular, Inc.
  • Medtronic PLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • REVA Medical, LLC
  • Terumo Corporation
  • Venturis Therapeutics, Inc.
  • WL Gore & Associates, Inc.
Product Code: MRR-69324464D29D

The Peripheral Arterial Disease Therapeutics Market was valued at USD 4.75 billion in 2023, expected to reach USD 5.14 billion in 2024, and is projected to grow at a CAGR of 8.73%, to USD 8.55 billion by 2030.

The scope and definition of the Peripheral Arterial Disease (PAD) therapeutics market encompass the diagnosis, treatment, and management of PAD, a condition characterized by narrowed arteries reducing blood flow to the limbs. The necessity for effective PAD therapeutics arises from the increasing prevalence of risk factors like diabetes, hypertension, and obesity. Application areas include pharmaceuticals (e.g., anti-platelet drugs, statins), medical devices (stents, angioplasty balloons), and lifestyle management programs aimed at improving patient outcomes. End-use sectors primarily involve hospitals, specialty clinics, and home care settings. Market insights reveal that key factors driving growth include advancements in minimally invasive treatments, increasing awareness about PAD, and a surge in the geriatric population prone to vascular disorders. Recent opportunities are present in the development of drug-eluting technologies and biologics, as well as integrated healthcare solutions offering both medical intervention and digital monitoring of patients. To capitalize on these opportunities, companies should focus on R&D investments in personalized medicine and partnerships with tech firms for digital health solutions. Despite the promising growth, the market faces limitations such as high costs of advanced therapies, regulatory hurdles, and challenges in patient adherence to treatment regimens. Moreover, the market's growth is constrained by limited access to healthcare in emerging regions and a lack of comprehensive diagnostic facilities. Innovative research areas include the exploration of gene therapy, regenerative medicine for arterial repair, and the development of AI technologies for early PAD detection and management. The market nature is dynamic, heavily influenced by technological advancements and changing healthcare policies. To ensure sustained business growth, companies should prioritize adaptable strategies that couple treatment innovation with patient-centric care models and consider potential collaborations for expanding access in underserved regions.

KEY MARKET STATISTICS
Base Year [2023] USD 4.75 billion
Estimated Year [2024] USD 5.14 billion
Forecast Year [2030] USD 8.55 billion
CAGR (%) 8.73%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peripheral Arterial Disease Therapeutics Market

The Peripheral Arterial Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of peripheral arterial disease with an increasing geriatric population
    • Increasing shift toward unhealthy lifestyles among people globally
    • Growing preference for minimally invasive endovascular procedures
  • Market Restraints
    • High cost associated with treatment of peripheral arterial disease
  • Market Opportunities
    • Research and development for advanced treatments for peripheral arterial disease
    • Growing product approvals for the treatment of peripheral arterial disease
  • Market Challenges
    • Lack of skilled professionals and doctors with proficiency in peripheral arterial disease devices

Porter's Five Forces: A Strategic Tool for Navigating the Peripheral Arterial Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peripheral Arterial Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peripheral Arterial Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peripheral Arterial Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peripheral Arterial Disease Therapeutics Market

A detailed market share analysis in the Peripheral Arterial Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peripheral Arterial Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peripheral Arterial Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Peripheral Arterial Disease Therapeutics Market

A strategic analysis of the Peripheral Arterial Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Peripheral Arterial Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alucent Biomedical Inc., AnGes, Inc., AngioDynamics, Inc., ARCA biopharma, Inc., B. Braun SE, Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cook Group Incorporated, Helixmith Co., Ltd., Koninklijke Philips N.V., LeMaitre Vascular, Inc., Medtronic PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, REVA Medical, LLC, Terumo Corporation, Venturis Therapeutics, Inc., and W. L. Gore & Associates, Inc..

Market Segmentation & Coverage

This research report categorizes the Peripheral Arterial Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Medications and Surgical Treatments. The Medications is further studied across Antihypertensives, Naftidrofuryl Oxalate, and Statins. The Surgical Treatments is further studied across Angioplasty and Artery Bypass Graft.
  • Based on Indication Stage, market is studied across Asymptomatic, Ischemic Rest Pain, Mild Claudication, Moderate/Severe Claudication, and Ulcers/Gangrene.
  • Based on End-Users, market is studied across Hospitals and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of peripheral arterial disease with an increasing geriatric population
      • 5.1.1.2. Increasing shift toward unhealthy lifestyles among people globally
      • 5.1.1.3. Growing preference for minimally invasive endovascular procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with treatment of peripheral arterial disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Research and development for advanced treatments for peripheral arterial disease
      • 5.1.3.2. Growing product approvals for the treatment of peripheral arterial disease
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled professionals and doctors with proficiency in peripheral arterial disease devices
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Peripheral Arterial Disease Therapeutics Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.2.1. Antihypertensives
    • 6.2.2. Naftidrofuryl Oxalate
    • 6.2.3. Statins
  • 6.3. Surgical Treatments
    • 6.3.1. Angioplasty
    • 6.3.2. Artery Bypass Graft

7. Peripheral Arterial Disease Therapeutics Market, by Indication Stage

  • 7.1. Introduction
  • 7.2. Asymptomatic
  • 7.3. Ischemic Rest Pain
  • 7.4. Mild Claudication
  • 7.5. Moderate/Severe Claudication
  • 7.6. Ulcers/Gangrene

8. Peripheral Arterial Disease Therapeutics Market, by End-Users

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Clinics

9. Americas Peripheral Arterial Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Peripheral Arterial Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Peripheral Arterial Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alucent Biomedical Inc.
  • 3. AnGes, Inc.
  • 4. AngioDynamics, Inc.
  • 5. ARCA biopharma, Inc.
  • 6. B. Braun SE
  • 7. Becton, Dickinson and Company
  • 8. BIOTRONIK SE & Co. KG
  • 9. Boston Scientific Corporation
  • 10. Cook Group Incorporated
  • 11. Helixmith Co., Ltd.
  • 12. Koninklijke Philips N.V.
  • 13. LeMaitre Vascular, Inc.
  • 14. Medtronic PLC
  • 15. Meril Life Sciences Pvt. Ltd.
  • 16. MicroPort Scientific Corporation
  • 17. REVA Medical, LLC
  • 18. Terumo Corporation
  • 19. Venturis Therapeutics, Inc.
  • 20. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY NAFTIDROFURYL OXALATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ARTERY BYPASS GRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASYMPTOMATIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ISCHEMIC REST PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MILD CLAUDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE/SEVERE CLAUDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ULCERS/GANGRENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 235. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023